Ascenta Pharma of Guangzhou Presents Data on Novel Cancer Drug

Ascenta Pharmaceuticals, a Guangzhou oncology drug startup, presented preclinical results of its AKR1C3 drug at the recent American Association for Cancer Research Annual Meeting in New Orleans. AKR1C3 is an enzyme that is up-regulated in many cancers, especially liver cancer. Ascenta's drug, AST-106, targets AKR1C3, using a prodrug approach to deliver cytotoxic agents directly to the tumor. Ascenta acquired Asian rights to the drug from Threshold Pharma of San Francisco. More details.... Stock Symbol: (NSDQ: THLD) Share this with colleagues: // //